Company Overview of Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes in the United States. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast grow...
Two Corporate Drive
South San Francisco, CA 94080
Founded in 2001
Key Executives for Five Prime Therapeutics, Inc.
Founder, Chairman, Chief Executive Officer and President
Total Annual Compensation: $525.0K
Chief Operating Officer and Director
Total Annual Compensation: $383.5K
Chief Strategy Officer and Secretary
Total Annual Compensation: $358.5K
Compensation as of Fiscal Year 2015.
Five Prime Therapeutics, Inc. Key Developments
Five Prime Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2017
Jan 9 17
Five Prime Therapeutics, Inc. expects net cash used in operations for fiscal year 2017 will be less than $120 million.
Five Prime Therapeutics, Inc. and Bristol-Myers Squibb Company Extend Research Term in Collaboration to Discover Novel Immuno-Oncology Therapies
Jan 4 17
Five Prime Therapeutics, Inc. announced that Bristol-Myers Squibb Company has exercised its option to extend the research term of its discovery collaboration agreement with Five Prime for the discovery, development and commercialization of immuno-oncology therapies directed toward targets in three undisclosed immune checkpoint pathways. The original collaboration agreement was established in March 2014 and focused on two undisclosed immune checkpoint pathways. In January 2016, the companies added a third immune checkpoint pathway to the collaboration. Bristol-Myers Squibb has now elected to extend the research term from its original ending date of March 2017 to March 2018, and will provide additional research funding for the 12-month extension of the research term. Bristol-Myers Squibb will utilize Five Prime's discovery capabilities to advance these three immuno-oncology programs toward the identification of drug candidates for continued research and development. Under the terms of the original agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize products directed toward certain protein targets in the three checkpoint pathways identified by Five Prime prior to and during the collaboration. Bristol-Myers Squibb paid an upfront fee of $20 million to Five Prime and will provide up to $11.6 million in research funding over the course of the entire research term. Five Prime will be eligible to receive up to $300 million in future development (including $5 million upon filing of the first IND application by Bristol-Myers Squibb), regulatory and sales-based milestone payments per collaboration product and tiered mid-single-digit rising to low-double-digit royalty payments on net sales of each product commercialized by Bristol-Myers Squibb.
Five Prime Therapeutics, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-10-2017 09:30 AM
Jan 3 17
Five Prime Therapeutics, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-10-2017 09:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Lewis T. Williams, Founder, Chairman, Chief Executive Officer and President.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|